-
Product Insights
NewAllergic Asthma – Drugs In Development, 2024
Empower your strategies with our Allergic Asthma – Drugs In Development, 2024 report and make more profitable business decisions. Allergic asthma is a type of asthma triggered by exposure to allergens, substances that induce an allergic reaction in susceptible individuals. When someone with allergic asthma encounters these triggers, their immune system responds by inflaming and constricting the airways, leading to symptoms of asthma. Common allergens that can trigger asthma include pollen, dust mites, pet dander, mold, cockroach droppings, and certain foods....
-
Product Insights
NewFood Allergy – Drugs In Development, 2024
Empower your strategies with our Food Allergy – Drugs In Development, 2024 report and make more profitable business decisions. Food allergies are immune system reactions to certain proteins in food. Symptoms range from mild itching to severe anaphylaxis, involving difficulty breathing and a drop in blood pressure, which can be life-threatening. Common allergens include peanuts, tree nuts, shellfish, eggs, milk, wheat, and soy. Strict avoidance and preparedness for accidental exposure are crucial. Diagnosis involves tests like skin prick or blood tests,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders Drug...
-
Product Insights
Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Systemic Lupus Erythematosus Pipeline Drugs Market Report Overview The inflammation triggered by Systemic Lupus Erythematosus (SLE) affects many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender, and hormones. The Systemic Lupus Erythematosus pipeline market research report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route...
-
Product Insights
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Asthma, a chronic disease involving the airways in the lungs, may occur with symptoms that include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The Asthma pipeline drugs market research report outlays comprehensive information on the Asthma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in...
-
Product Insights
Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atopic Dermatitis is an itchy inflammation of skin. Signs and symptoms of Atopic Dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender. The Atopic Dermatitis - Drugs In Development research report provides a comprehensive overview on the...
-
Product Insights
Dermatomyositis Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dermatomyositis Clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Competitor Landscape: Lupus
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Product Insights
Dermatomyositis Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Dermatomyositis Global Clinical Trials Review, H1, 2019" provides an overview of Dermatomyositis clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...